PDUFA VIII: What the FDA's Next User Fee Deal Changes

The FDA and the drug industry have finished the technical deal for the next five years of prescription drug user fees, known as PDUFA VIII ^[1]. Review clocks stay the same. The new parts are a third-party audit of first-cycle reviews, new meetings about manufacturing facilities and a fee cut for sponsors that run early trials in the United States ^[2][3][4].

None of it is law yet. Congress has to pass a reauthorization before the current program expires on September 30, 2027 ^[5][6]. This guide explains what the proposed commitment letter keeps, what it changes and what it means for people who build and file drug applications.

What PDUFA is and why the 2027 deadline matters

PDUFA lets the FDA collect fees from companies to pay for the review of human drug applications ^[7]. Congress first passed it in 1992 for five years. It has been renewed every five years since, most recently by the FDA User Fee Reauthorization Act of 2022, which runs through fiscal year 2027 ^[7].

Each renewal comes with a commitment letter. It is a side agreement in which the FDA promises review goals and process changes in return for the fees. The fees add to the money Congress appropriates for drug review. By law they cannot replace it ^[6].

The stakes are about speed. The U.S. Chamber of Commerce says the FDA averaged more than 29 months to review new drug applications in 1992 ^[6]. It puts today's median approval times at 12 months for standard review and 8 months for priority review ^[6]. The Chamber warns that a lapse in fee authority would risk longer reviews and slower access to new medicines ^[6].

The process for this cycle is set by statute. The FDA held a kickoff public meeting on July 14, 2025 ^[7]. It then negotiated with industry and held monthly consultations with stakeholders from November 2025 through May 2026 ^[7]. Minutes from a May 15, 2026 negotiation meeting confirmed that technical talks had ended ^[1].

The FDA released the proposed letter on August 13, 2026 ^[3]. A Federal Register notice followed the next day ^[7]. The agency held a hybrid public meeting on September 16, and written comments closed on October 16 ^[7]. The FDA must send its final recommendations to Congress by January 15, 2027 ^[8][9]. Its own timeline expects congressional briefings and reauthorization between January and September 2027 ^[8].

What stays the same

The core review goals do not change. The goals for new drug and biologic applications, and for manufacturing supplements, are the same as under PDUFA VII ^[3].

That means the FDA still aims to act on 90% of standard new molecular entity (NME) applications and original biologics licence applications within 10 months of the 60-day filing date ^[2]. Priority applications keep a 6-month goal ^[2]. Prior approval manufacturing supplements keep a 4-month goal ^[2]. A sponsor still gets only one goal date extension per review cycle ^[2].

The FDA describes the new letter as about 20 pages shorter than the last one ^[8]. Much of the trimming comes from dropping one-time PDUFA VII commitments that are done ^[8][7]. Two pilots end: the Split Real-Time Application Review (STAR) pilot and the CMC Development and Readiness Pilot ^[7][3]. CMC stands for chemistry, manufacturing and controls, the quality part of a filing.

What changes in premarket review

A third-party audit of first-cycle reviews

Starting in fiscal year 2028, an independent contractor will assess first-cycle review outcomes and communication between the FDA and sponsors ^[2]. The stated aims are fewer complete response letters in the first cycle, fewer missed goal dates and fewer review extensions ^[3]. A complete response letter is the FDA's notice that it cannot approve an application as submitted.

The assessment also covers communication on pivotal protocols, including how long the FDA takes to respond on a protocol and its statistical analysis plan ^[2]. The schedule is fixed. An interim report is due by March 31, 2030, a public workshop by June 30, 2030 and a final report by March 31, 2032 ^[2][9].

Faster attention for pivotal protocols

Sponsors will be able to flag a submission as a "Pivotal Protocol" in the cover letter and state the planned study start date ^[4]. The FDA will update its internal procedures at both drug and biologics review offices by the end of fiscal year 2028 to prioritize these protocols ^[4].

More control over meeting format

For pre-IND, Type C, Type D and INTERACT meetings, sponsors may ask for a face-to-face meeting but must explain why ^[4]. If the FDA decides a written response is enough, it has to give a specific reason ^[3][4]. Sponsors with products under several INDs across therapeutic areas can also ask for multi-divisional meetings within an existing meeting type ^[3][4].

The FDA will publish revised draft guidance on formal meetings by September 30, 2028 ^[9]. After the late-cycle meeting, information requests will also describe the issue that triggered them ^[4]. That small change could save review teams and sponsors a round of guesswork.

Pilots become standard practice

Several PDUFA VII pilots move into routine review. Model-informed drug development meetings become Type C meetings, and the quarterly cap on requests goes away ^[3]. The Complex Innovative Design program becomes part of standard review practice ^[4][5]. Real-world evidence no longer runs as a separate pilot, though the FDA will keep reporting each year on submissions that use it ^[4][5].

The Rare Disease Endpoint Advancement pilot phases into the standard meeting framework through fiscal 2029, with up to 4 proposals accepted in fiscal 2028 and 6 in fiscal 2029 ^[5]. From fiscal 2030 to 2032 it becomes a Type C meeting ^[5]. The FDA also plans up to 10 Rare Disease Innovation, Science, and Exploration (RISE) workshops, at least one a year ^[9][5]. Rare disease staff at the drug review office will join review teams for rare disease programs ^[5].

For cell and gene therapy, the letter shifts the program "from growth to maintenance," with a focus on hiring staff who have specialized expertise ^[4].

The manufacturing piece: a facility lifecycle program

Manufacturing sites can sink an otherwise approvable application. The Chamber calls facility issues a leading cause of complete response letters and approval delays ^[6]. PDUFA VIII answers with a new CMC facility lifecycle program built on earlier and more structured contact ^[4].

• Pre-submission facility meeting. One per application, for new drug and biologics applications including supplements, held three to six months before submission ^[4].
• Advance notice of inspection. For original applications, the FDA will tell the applicant at least 60 days before a pre-approval or pre-licence inspection, and no later than mid-cycle ^[4].
• Post-inspection meeting. For original applications, the sponsor can meet the FDA after the inspection. The FDA may then extend the goal date by three months, and only one such extension is allowed ^[4].
• Post-action meeting. A Type A meeting is available after a complete response letter caused by inspection deficiencies ^[4].

The FDA says it will strive to publish draft guidance on the program by October 1, 2028 ^[9]. An independent third party will run a public workshop by September 30, 2030 ^[4]. A final assessment report is due within nine months after that workshop's comment period closes ^[4][9].

Proposed change	Who it applies to	Key date
Third-party first-cycle review assessment	NME NDAs and original BLAs, plus labelling talks on efficacy supplements [4]	Final report by March 31, 2032 [2]
Pivotal protocol prioritization	Sponsors flagging pivotal protocols [4]	Procedures updated by end of FY 2028 [4]
Revised formal meetings guidance	Multi-divisional and written-response meetings [9]	Draft by September 30, 2028 [9]
CMC facility lifecycle draft guidance	NDAs and BLAs [4]	Target October 1, 2028 [9]
Five-year financial plan	FDA user fee program [9]	End of Q2 FY 2028 [9]
Enterprise performance assessment	FDA user fee program [9]	Report by March 31, 2029 [9]

The fee changes Congress must write into law

The most political part of the package is the fee structure. These changes need legislation, not just an FDA commitment ^[4].

First, the application fee would drop by 50% if the application includes clinical data from at least one phase 1 trial anchored in the United States and started after October 1, 2027 ^[4][5]. Second, the small business fee waiver would be limited to U.S.-based companies ^[3][4]. FDA slides describe these as companies organized under the laws of a state ^[8]. Third, the first supplement for a non-orphan indication would carry a fee of 50% of a full application fee ^[4]. The orphan exemption would be limited to products approved only for orphan indications ^[4].

RAPS ties these items to the administration's push to bring research and manufacturing to the United States ^[3]. The American Action Forum calls the fee design a closely watched point of contention ^[1]. It reports that industry wanted faster IND review alongside the domestic incentive, and the FDA declined to negotiate that within PDUFA ^[1].

The money side also tightens. The base revenue amount falls by about $56.0 million for administrative efficiencies and rises by about $7.8 million for net new positions, a net cut of $48.3 million ^[9]. The maximum operating reserve drops from 14 weeks to 12 weeks ^[8]. The capacity planning adjustment will not apply until restaffing, and it is capped at a 3% increase per year ^[8].

The FDA will publish a five-year financial plan by the end of the second quarter of fiscal 2028 and update it every year ^[9]. A third-party enterprise performance assessment is due by March 31, 2029 ^[9]. That review could find efficiencies that reduce future fee revenue ^[8].

What the evidence shows

The public record points to a deal that fixes process rather than rewriting the rules. Three patterns stand out.

The target is the first cycle. The review clocks are unchanged ^[3]. The new effort goes into getting more applications right the first time, through the third-party audit, clearer late-cycle requests and the facility meetings ^[2][4]. The Chamber says too many approvable applications get complete response letters ^[6].

Staffing is a central risk. Holland & Knight notes that the FDA cited high staff attrition during PDUFA VII ^[5]. A personnel set-aside reserves money to restaff at a level consistent with fiscal 2025 ^[3][9]. The FDA will keep publishing quarterly hiring updates with net hires at its drug and biologics centres ^[8]. The American Action Forum warns that turnover and tight resources could become a central risk to delivery ^[1].

Support is broad but not uniform. PhRMA and BIO both back the agreement, and PhRMA's Stephen Ubl urged Congress to move swiftly ^[3]. The Chamber calls it a measured step forward ^[6]. The American Action Forum sees an incremental package rather than a sweeping one ^[1]. Patient groups raised concerns at an earlier stakeholder meeting, including whether efficiency could crowd out safety ^[1]. The September meeting heard from 22 public speakers, including Public Citizen and NORD ^[8].

What it means for people in the industry

Regulatory affairs. Meeting requests need more care. Teams that want a face-to-face pre-IND, Type C, Type D or INTERACT meeting will need to explain why, and the FDA can still answer in writing ^[4]. Pivotal protocols can be flagged for priority ^[4]. Pilot programs such as model-informed drug development meetings become regular options, which makes them easier to plan around ^[3].

CMC and quality. The facility lifecycle program rewards readiness. A pre-submission facility meeting three to six months before filing gives quality teams a formal window to raise site issues ^[4]. The 60-day inspection notice gives sites time to prepare ^[4]. Inspection readiness work will likely start earlier in the project plan.

Clinical operations and business development. Where a phase 1 trial runs could now affect the application fee ^[4][5]. Companies weighing first-in-human sites in Canada, Australia or Europe will want to know how "anchored in the United States" is defined in the final law. Small companies incorporated outside the United States should also watch the waiver wording, since the slides refer to companies organized under state law ^[8].

Hiring. The commitments assume the FDA can rebuild review capacity ^[3][5]. For job seekers with review, CMC or rare disease experience, that is worth watching through 2027. You can follow open roles on our jobs page and the reauthorization debate on PharmoniQ news.

Timing is the other planning factor. The current program runs to September 30, 2027 ^[5][6]. Teams with filings planned for late 2027 should track the bill closely.

Key takeaways

• PDUFA VIII would run from fiscal 2028 to 2032, and Congress must act before PDUFA VII expires on September 30, 2027 ^[5][6].
• Review goals stay the same: 10 months for standard and 6 months for priority NME and original biologics applications ^[2][3].
• A third-party audit will study first-cycle reviews, with a final report due by March 31, 2032 ^[2].
• A new CMC facility lifecycle program adds a pre-submission facility meeting, 60-day inspection notice and post-inspection meetings ^[4].
• Proposed fee changes include a 50% cut for applications with U.S.-anchored phase 1 data and a U.S.-only small business waiver ^[3][4].
• Base fee revenue would fall by a net $48.3 million, with money set aside to restaff ^[9].
• Staff turnover could become a central execution risk, according to the American Action Forum ^[1].

References

1. PDUFA VIII: The Technical Deal Is Done. The Hard Part Comes Next.. American Action Forum, May 29, 2026.
2. PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2028 Through 2032. U.S. Food and Drug Administration.
3. PDUFA VIII: FDA outlines goals, program enhancements in commitment letter. RAPS Regulatory Focus, Aug 13, 2026.
4. FDA Releases Proposed PDUFA VIII Commitment Letter. Arnold & Porter, Aug 19, 2026.
5. FDA Releases Draft GDUFA, PDUFA Commitment Letters as User Fee Reauthorizations Move Forward. Holland & Knight, Aug 18, 2026.
6. U.S. Chamber Comments on FDA's PDUFA VIII Reauthorization Process. U.S. Chamber of Commerce, Oct 15, 2026.
7. Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments. Federal Register, Aug 14, 2026.
8. Public Meeting on the Recommendations and Proposed Enhancements for PDUFA VIII. U.S. Food and Drug Administration, Sep 16, 2026.
9. PDUFA VIII Pushes Forward: Proposed Commitment Letter Outlines Updates to Drug Review Process. Akin Gump, Aug 26, 2026.